Research progress on dendritic cell vaccines in cancer immunotherapy

Yu, Jifeng; Sun, Hao; Cao, Wenhui; Song, Yongping; Jiang, Zhongxing

doi:10.1186/s40164-022-00257-2

Cited by 99 publications

(83 citation statements)

References 176 publications

(227 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One direction in DC-based immunotherapies is the attempt to amplify cDC1′s tumor recognition [ 255 ]. Another is based on immunological memory: a DC vaccine (DCV) can initiate an anti-tumoral T-cell response, and a selective killing of the tumor cells [ 249 , 256 ]. If theoretically, a personalized DCV can prevent a tumor recurrence [ 256 ], the clinical response to DCV immunotherapy in GBM patients is variable (from no response to significant response) [ 248 ].…”

Section: Other Immune Cells In Tumor Microenvironment and New Techniq...mentioning

confidence: 99%

“…Another is based on immunological memory: a DC vaccine (DCV) can initiate an anti-tumoral T-cell response, and a selective killing of the tumor cells [ 249 , 256 ]. If theoretically, a personalized DCV can prevent a tumor recurrence [ 256 ], the clinical response to DCV immunotherapy in GBM patients is variable (from no response to significant response) [ 248 ]. However, there are promising effects of DCV, such as the Tregs reduction in relapsed patients with high-grade glioma [ 251 ].…”

Section: Other Immune Cells In Tumor Microenvironment and New Techniq...mentioning

confidence: 99%

“…Immunotherapeutic approaches can be active and passive and can include anti-checkpoint inhibitors, TME remodeling, stimulation of tumor immunogenicity (DC vaccines, oncolytic viruses), and genetic engineering (adoptive T-cell therapies or chimeric antigen receptor T cell therapy); all those strategies aim to help the immune system to win the fight against cancer [ 248 , 249 , 255 , 256 ].…”

Section: Cell-targeting Therapiesmentioning

confidence: 99%

See 2 more Smart Citations

Glioblastoma Microenvironment and Cellular Interactions

Crivii

Boșca

Melincovici

et al. 2022

Cancers

View full text Add to dashboard Cite

The central nervous system (CNS) represents a complex network of different cells, such as neurons, glial cells, and blood vessels. In tumor pathology, glial cells result in the highest number of cancers, and glioblastoma (GB) is considered the most lethal tumor in this region. The development of GB leads to the infiltration of healthy tissue through the interaction between all the elements of the brain network. This results in a GB microenvironment, a complex peritumoral hallo composed of tumor cells and several non-tumor cells (e.g., nervous cells, stem cells, fibroblasts, vascular and immune cells), which might be the principal factor for the ineffective treatment due to the fact that the microenvironment modulates the biologic status of the tumor with the increase in its evasion capacity. Crosstalk between glioma cells and the brain microenvironment finally inhibits the beneficial action of molecular pathways, favoring the development and invasion of the tumor and its increasing resistance to treatment. A deeper understanding of cell–cell interactions in the tumor microenvironment (TME) and with the tumor cells could be the basis for a more efficient therapy.

show abstract

Section: Other Immune Cells In Tumor Microenvironment and New Techniq...mentioning

confidence: 99%

Section: Other Immune Cells In Tumor Microenvironment and New Techniq...mentioning

confidence: 99%

Section: Cell-targeting Therapiesmentioning

confidence: 99%

See 1 more Smart Citation

Glioblastoma Microenvironment and Cellular Interactions

Crivii

Boșca

Melincovici

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…Dendritic cells (DCs) as potent antigen-presenting cells (APCs), can internalize tumor lysates or antigens and induce antitumor responses by CD8 + cytotoxic T lymphocyte (CTLs) and CD4 + T helper (Th) cells [ 11 ]. Regrettably, the objective clinical immune response rates achieved with DC-based vaccines are less than 15% [ 12 , 13 ]. Immunosuppression occurring in the tumor microenvironment or T-cell dysfunction in CML patients impairs the immune activity of DCs [ 14 , 15 ].…”

Section: Introductionmentioning

confidence: 99%

Modified dendritic cell-derived exosomes activate both NK cells and T cells through the NKG2D/NKG2D-L pathway to kill CML cells with or without T315I mutation

Huang

Chen

et al. 2022

Exp Hematol Oncol

View full text Add to dashboard Cite

Background Tyrosine kinase inhibitors have achieved quite spectacular advances in the treatment of chronic myeloid leukemia (CML), but disease progression and drug resistance that related to the T315I mutation, remain major obstacles. Dendritic cell-derived exosomes (Dex) induce NK cell immunity, but have yet to achieve satisfactory clinical efficacy. An approach to potentiate antitumor immunity by inducing both NK- and T-cell activation is urgently needed. Retinoic acid early inducible-1γ (RAE-1γ), a major ligand of natural killer group 2 member D (NKG2D), plays an important role in NK-cell and T-lymphocyte responses. We generated RAE-1γ enriched CML-specific Dex (CML-RAE-1γ-Dex) from dendritic cells (DCs) pulsed with lysates of RAE-1γ-expressing CML cells or T315I-mutant CML cells, aiming to simultaneously activate NK cells and T lymphocytes. Methods We generated novel CML-RAE-1γ-Dex vaccines, which expressed RAE-1γ, and were loaded with CML tumor cell lysates. NK cells or T lymphocytes were coincubated with CML-RAE-1γ-Dex vaccines. Flow cytometry was performed to evaluate the activation and proliferation of these immune cells. Cytokine production and cytotoxicity toward CML cells with or without the T315I mutation were detected by ELISPOT, ELISA and LDH assays. CML models induced by BCR-ABL or BCR-ABLT315I were used to determine the immunological function of Dex in vivo. Results Herein, CML-RAE-1γ-Dex were prepared. CML-RAE-1γ-Dex effectively enhanced the proliferation and effector functions of NK cells, CD4+ T cells and CD8+ T cells, which in turn produced strong anti-CML efficacy in vitro. Moreover, CML-RAE-1γ-Dex-based immunotherapy inhibited leukemogenesis and generated durable immunological memory in CML mouse models. Similar immune responses were also observed with imatinib-resistant CML cells carrying the T315I mutation. Conclusions This approach based on CML-RAE-1γ-Dex vaccines may be a promising strategy for CML treatment, especially for cases with the T315I mutation.

show abstract

“…Interestingly, a subcategory of APC, namely dendritic cells (DC), is particularly interesting for immunotherapy as they are capable of capturing and processing tumor antigens, allowing T cell recognition, and subsequent expansion, to fight cancer [ 7 ]. DC-based cancer vaccines have been explored as a promising therapeutic opportunity [ 8 , 9 ], as cancer vaccination offers distinct advantages over standard therapies, such as specificity, lower toxicity, and long-term effects due to immunological memory [ 10 ]. The selection of the appropriate antigen plays a key role in the development of a DC-targeted vaccine.…”

Section: Introductionmentioning

confidence: 99%

Exploring chitosan-shelled nanobubbles to improve HER2 + immunotherapy via dendritic cell targeting

Argenziano

Occhipinti

Scomparin

et al. 2022

Drug Deliv. and Transl. Res.

View full text Add to dashboard Cite

Immunotherapy is a valuable approach to cancer treatment as it is able to activate the immune system. However, the curative methods currently in clinical practice, including immune checkpoint inhibitors, present some limitations. Dendritic cell vaccination has been investigated as an immunotherapeutic strategy, and nanotechnology-based delivery systems have emerged as powerful tools for improving immunotherapy and vaccine development. A number of nanodelivery systems have therefore been proposed to promote cancer immunotherapy. This work aims to design a novel immunotherapy nanoplatform for the treatment of HER2 + breast cancer, and specially tailored chitosan-shelled nanobubbles (NBs) have been developed for the delivery of a DNA vaccine. The NBs have been functionalized with anti-CD1a antibodies to target dendritic cells (DCs). The NB formulations possess dimensions of approximately 300 nm and positive surface charge, and also show good physical stability up to 6 months under storage at 4 °C. In vitro characterization has confirmed that these NBs are capable of loading DNA with good encapsulation efficiency (82%). The antiCD1a-functionalized NBs are designed to target DCs, and demonstrated the ability to induce DC activation in both human and mouse cell models, and also elicited a specific immune response that was capable of slowing tumor growth in mice in vivo. These findings are the proof of concept that loading a tumor vaccine into DC-targeted chitosan nanobubbles may become an attractive nanotechnology approach for the future immunotherapeutic treatment of cancer. Graphical abstract

show abstract

Research progress on dendritic cell vaccines in cancer immunotherapy

Cited by 99 publications

References 176 publications

Glioblastoma Microenvironment and Cellular Interactions

Glioblastoma Microenvironment and Cellular Interactions

Modified dendritic cell-derived exosomes activate both NK cells and T cells through the NKG2D/NKG2D-L pathway to kill CML cells with or without T315I mutation

Exploring chitosan-shelled nanobubbles to improve HER2 + immunotherapy via dendritic cell targeting

Contact Info

Product

Resources

About